08 September 2015 : Review article
Stem Cell-Assisted Lipotransfer and the Private Breast Surgery Market
Bartłomiej NoszczykEDOI: 10.12659/AOT.894134
Ann Transplant 2015; 20:526-531
Abstract
Over the last decade autologous fat from subcutaneous tissue has been used by plastic surgeons for face volumization. It has also been used with growing frequency for aesthetic breast enhancement. Currently, experts in this field are becoming increasingly aware of the potential of fat for breast reconstruction. However, the safety of fat transfers to post-mastectomy defects has been called into question in recent debates due to the, albeit rare, observations of their possible influence on local cancer recurrence. The majority of concerned opinions are based on the safety of fat supplementation with additional amounts of adipose mesenchymal and stem cells. In experimental conditions, these cells were shown to create pathophysiological microenvironments and promote neoplastic transitions. This raises the question as to whether breast reconstruction with enriched fat is sufficiently safe to be performed without scientific justification and whether the present legal regulations are sufficient to guarantee patient safety in small facilities. In a number of circumstances, patients who have undergone treatment in profit-oriented offices, outside the system of oncological or surgical centers, might have been left without any long-term cancer surveillance. Valid opinions have also been expressed on the grounds of the ethical doubts concerning the advertising used by cosmetic practitioners who, on occasion, tend to overemphasize the putative benefits of stem cell applications despite the scant support in evidence-based medicine. Real progress in this field is possible only in scientific research that relies on bioethical evaluation, properly planned clinical trials, and the judgment of peers.
Keywords: Adipose Tissue, Mammaplasty, Stem Cell Transplantation
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






